Cystadenocarcinoma

A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)

Also Known As:

Networked: 265 relevant articles (6 outcomes, 19 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Carcinoma (Carcinomatosis)
3.	Squamous Cell Carcinoma (Epidermoid Carcinoma)
4.	Lymphatic Metastasis
5.	Cholangiocarcinoma

Experts

1.	Nakanuma, Yasuni: 3 articles (11/2011 - 09/2006)
2.	Zen, Yoh: 3 articles (11/2011 - 09/2006)
3.	Xu, Hui-Xiong: 2 articles (01/2022 - 12/2009)
4.	Lim, Jae Hoon: 2 articles (11/2011 - 01/2002)
5.	Mizuguchi, Yasunori: 2 articles (09/2010 - 08/2003)
6.	Hai, Seikan: 2 articles (12/2003 - 01/2003)
7.	Hirohashi, Kazuhiro: 2 articles (12/2003 - 01/2003)
8.	Kinoshita, Hiroaki: 2 articles (12/2003 - 01/2003)
9.	Kubo, Shoji: 2 articles (12/2003 - 01/2003)
10.	Shuto, Taichi: 2 articles (12/2003 - 01/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Cystadenocarcinoma:

1.	MucinsIBA 01/01/1983 - "Absorption of the antiserum with mucinous ovarian cystadenocarcinoma fluid eliminated generalized mucin staining, and only pancreatic ducts and colonic goblet cells were positive. " 01/01/1997 - "Histologically, the cystic component was lined by mucin-producing, columnar to cuboidal epithelium composed of benign to atypical to overtly malignant cells (cystadenocarcinoma). " 05/15/1992 - "Nine cases of biliary cystadenocarcinoma of the liver were studied, with emphasis on its clinicopathologic features, mucin profiles, and immunohistochemical characteristics. " 03/15/1999 - "In each Cox regression model, both those including cystadenocarcinoma and mucin-producing tumors and those that did not, p27Kip1 expression proved to be an independent predictor for overall survival by multivariate analysis. " 03/15/1999 - "After excluding cases of cystadenocarcinoma and mucin-producing tumors, the survival advantage for patients with p27Kip1 positive tumors remained apparent (P = 0.024). "
2.	AntigensIBA 11/06/2021 - "A high prostatic-specific antigen with a large pelvic mass indicates a prostatic cystadenocarcinoma." 08/01/1983 - "Tumour-associated antigens for cystadenocarcinoma of the ovary." 03/01/1981 - "Only one of five mucinous ovarian cystadenocarcinomas was positive for colonic mucoprotein antigen. " 03/01/1981 - "An antiserum prepared against normal colon-derived colonic mucoprotein antigen and appropriately absorbed with mucinous ovarian cystadenocarcinoma fluid had reactivity limited to the colon and cecum when tested by immunoperoxidase against various normal adult tissue specimens. " 02/01/1979 - "Circulating ovarian cystadenocarcinoma-associated antigen serum levels were positive in 69.8% of patients and correlated with response to chemotherapy in 70% of patients. "
3.	Progestins (Progestagens)IBA 01/01/1983 - "Progestin treatment was effective in cases of endometrioid cystadenocarcinoma, particularly, in those of hormone-producing form." 02/01/1979 - "A patient was successfully treated by surgery, progestogens and chlorambucil for a poorly differentiated cystadenocarcinoma of the ovary. "
4.	Hormones (Hormone)IBA 04/01/2016 - "Hormone production by the cystadenocarcinoma was the predisposing factor that induced pyometra, mucosal hyperplasia, and vaginal fold prolapse in the dog. " 01/01/1983 - "Progestin treatment was effective in cases of endometrioid cystadenocarcinoma, particularly, in those of hormone-producing form."
5.	Androgen Receptors (Androgen Receptor)IBA 09/01/2017 - "In particular, attention to the apocrine phenotype of SDC and expression of androgen receptor (AR) by immunohistochemistry has improved the diagnostic accuracy and showed how SDC can be reliably distinguished from its morphologic mimics (i.e., other salivary gland carcinomas with high grade transformation, low grade cribriform cystadenocarcinoma, and squamous cell carcinomas involving parotid). "
6.	Protein Isoforms (Isoforms)IBA 12/01/2016 - "We used TCGA database to analyze the correlation between expressions of the NOX regulatory subunits, NOS isoforms, and BRCA1 in the 3 cancer research studies: breast invasive carcinoma, ovarian cystadenocarcinoma, and lung adenocarcinoma. " 01/01/2012 - "In this study, we examined the expression of all isoforms of CD44 by immunohistochemistry in 3 cases of biliary cystadenoma, 15 cases of non-invasive cystadenocarcinoma (CAC) bile duct tumors, and 67 cases of the aggressive bile duct tumor, cholangiocarcinoma (CCA). " 12/01/2003 - "Expression of transforming growth factor-beta isoforms in the skin, kidney, pancreas and bladder in a German shepherd dog affected by renal cystadenocarcinoma and nodular dermatofibrosis." 12/01/2003 - "The present study was performed to assess the expression of isoforms 1, 2 and 3 of transforming growth factor (TGF)-beta in skin nodular dermatofibrosis lesions, kidney, bladder and pancreas from a 10-year-old female German shepherd dog (GSD) affected by renal cystadenocarcinoma and nodular dermatofibrosis (RCND) compared with normal GSDs (n = 2). "
7.	Mucin-1 (CA 15-3 Antigen)IBA 12/01/1999 - "Our previous immunohistochemical study on intrahepatic bile duct tumors showed that invasive cholangiocarcinoma (ICC) with a poor outcome expressed MUC1 mucin but was negative for MUC2 mucin, whereas bile duct cystadenocarcinoma (BDCC) with a favorable outcome was MUC1 negative and MUC2 positive. " 12/01/1997 - "In the present study of pancreas and intrahepatic bile duct tumors, MUC1 mucin (membrane bound mucin detected by monoclonal antibody, DF3) was highly expressed in invasive ductal carcinomas of the pancreas (IDC) and invasive cholangiocarcinomas of the liver (ICC), which show invasive growth and a poor prognosis, but it was rarely expressed in intraductal papillary mucinous tumors of the pancreas (IPMT) and bile duct cystadenocarcinomas of the liver (BDCC), which show a favorable prognosis. " 05/01/1989 - "Cryostat sections of human skin were stained with monoclonal antibodies to involucrin, a range of cytokeratins, epithelial membrane antigen (EMA), and an ovarian cystadenocarcinoma antibody (OM1) to identify combinations of antibodies that could be used to discriminate between basal and differentiated sebocytes and other cell types present in the pilosebaceous unit. "
8.	Carcinoembryonic AntigenIBA 02/01/2007 - "We compared endoscopic ultrasonography-guided (EUS-guided) fine needle aspiration biopsy combined with cyst fluid carcinoembryonic antigen (CEA), CA19-9 examination with computed tomography (CT), B-ultrasonography (B-US) and serum CEA and CA19-9, to explore methods of early diagnosis of cystadenocarcinoma of the pancreas. " 04/01/1998 - "A carcinoembryonic antigen level of >400 ng/ml had a 57% sensitivity and a 100% specificity for distinguishing mucinous tumours and cystadenocarcinomas from pseudocysts. " 05/01/1979 - "Characterization of the carcinoembryonic antigen activity associated with cyst fluids of mucinous ovarian cystadenocarcinoma." 08/01/1978 - "Cystadenocarcinoma and carcinoembryonic antigen (CEA)." 01/01/1986 - "Cystadenoma and cystadenocarcinoma of the liver: localization of carcinoembryonic antigen."
9.	CarbohydratesIBA 10/01/1999 - "This rare condition was detected in a 61-year-old man who underwent left trisegmentectomy of liver under a suspected diagnosis of cystadenocarcinoma because of elevated serum levels of carbohydrate antigen (CA) 19-9 and DUPAN 2, and the presence of an intracystic structure. " 07/01/2003 - "Carbohydrate antigen 19-9 > 50,000 U/ml had a 15% sensitivity and a 81% specificity to distinguish mucinous cysts from other cystic lesions, whereas it had a 86% sensitivity and a 85% specificity to distinguish cystadenocarcinoma from other cystic lesions. " 09/21/2014 - "Preoperative levels of cancer antigen 125 (12.51 ± 9.31 vs 23.20 ± 21.86, P < 0.05) and carbohydrate antigen 19-9 (22.56 ± 26.30 vs 72.55 ± 115.99, P < 0.05) were higher in the cystadenocarcinoma subgroup than in the cystadenoma subgroup. " 01/01/2003 - "The remaining patient had elevated serum concentrations of carcinoembryonic antigen and carbohydrate antigen 19-9, even though preoperative imaging studies of the hepatic cystic lesion revealed no imaging features of cystadenocarcinoma. " 01/01/1994 - "The histological findings revealed a well-differentiated cystadenocarcinoma of the appendix, and immunohistochemical staining of the epithelium and mucinous implants in the mass demonstrated a positive reaction for carcinogenic antigens, including carcinoembryonic antigen and carbohydrate antigen."
10.	Tumor Biomarkers (Tumor Markers)IBA 11/01/2008 - "It is also difficult to differentiate biliary cystadenoma from biliary cystadenocarcinoma preoperatively by imaging studies or tumor markers. " 01/01/2006 - "But tumor markers cannot distinguish cystadenocarcinoma from cystadenoma or both from other cystic lesions of liver. " 01/01/1993 - "CA 125 has been established as an important tumor marker for monitoring patients diagnosed with nonmucinous ovarian cystadenocarcinoma although it has also been shown to be expressed by other carcinomas, normal epithelial tissues, and fetal tissues. " 02/15/1982 - "it was concluded that primitive cells in inclusion cysts elaborate the same tumor markers found in serous cystadenoma and cystadenocarcinoma of the ovary. " 07/01/1983 - "The following serum tumor markers are elevated above normal levels in 50 percent or more of patients with various malignant neoplasms: Alpha-fetoprotein in yolk sac tumors, hepatomas, retinoblastomas, embryonal carcinomas, breast carcinomas, and carcinomas of uterine cervix; Carcinoembryonic antigen in colon carcinomas, choriocarcinomas, pancreatic carcinomas, medullary thyroid carcinomas, osteosarcomas, retinoblastomas, ovarian cystadenocarcinomas, mycosis fungoides, hepatomas, esophageal carcinomas, adenocarcinomas of uterine cervix, lung carcinomas, carcinomas of small intestine, urinary bladder carcinomas, and renal cell carcinomas; Human chorionic gonadotrophin in choriocarcinomas, malignant interstitial cell tumors of testis, non seminomatous tumors of testis, embryonal carcinomas, and pancreatic carcinomas. "

Therapies and Procedures

1.	Hepatectomy 05/01/2011 - "The mainstay of treatment is complete resection, either by enucleation or by formal hepatectomy, since incomplete removal entails not only constant recurrence but also the risk of malignant transformation to cystadenocarcinoma. " 04/11/2019 - "Based on additional clinical examinations, biliary cystadenocarcinoma was undeniable, and laparoscopy-assisted extended right hepatectomy was performed for diagnostic and therapeutic purposes. " 01/01/2013 - "We preoperatively diagnosed this lesion as cystadenocarcinoma or CE and performed a left hepatectomy. " 03/01/2003 - "An extended left hepatectomy was performed on the basis of a presumptive diagnosis of a cystadenocarcinoma. " 01/01/2001 - "Systematic hepatectomy was recommended as the initial treatment in consideration of the features of cystadenocarcinoma."
2.	Therapeutics 04/01/1997 - "The Authors report their experience and a review of the Literature trying to establish the criteria for the classification, diagnosis and therapy of pancreatic cystadenocarcinoma." 01/01/1990 - "Cystadenocarcinoma of the pancreas: neo-adjuvant therapy and CEA monitoring." 04/15/1980 - "Cystadenocarcinoma of the ovary in a 4-year-old: benign transformation during therapy." 01/01/2021 - "Given that, in our case, a single course of combined ICI therapy induced a complete response in the unresectable and lymph node metastases from the cystadenocarcinoma and the multiple lung nodules, ICIs, including combined therapy, could be a promising treatment for advanced cystadenocarcinoma." 05/01/2020 - "Based on our experience, we emphasize that long-term follow-up and/or careful examination are necessary in patients with cystadenocarcinoma, especially in patients with lymph node metastasis during the initial surgical therapy."
3.	Laparotomy 01/01/2010 - "The aim of this study was to assess management of a consecutive series of patients who underwent laparotomy for a suspected cystadenoma or cystadenocarcinoma. " 10/28/2014 - "On the presumptive diagnosis of a cystadenoma or cystadenocarcinoma, patient underwent laparotomy. " 03/01/2010 - "On diagnostic laparotomy peritoneal infiltrations were observed and pathologic examination revealed a biliary cystadenocarcinoma and peritonitis carcinomatosa was diagnosed. " 10/01/2004 - "In the previous 12 patients managed with laparotomy, 6/12 patients had biliary epithelium alone; the other 6 also contained MS with 1 patient exhibiting intestinal metaplasia and cystadenocarcinoma. " 01/01/1990 - "The authors present a case history of a patient whose most recent relapse occurred 7 years after the initial laparotomy carried out for bilateral ovarian stage III cystadenocarcinoma diagnosed by biological follow-up (CA 125) which occurred because of isolated splenic metastases which were identified thanks to ultrasound examination. "
4.	Punctures 09/01/1986 - "[Echography-guided puncture of a cystadenocarcinoma of the pancreas]." 01/01/1953 - "[Studies on cytology and cytochemistry of cilioepithelial tumor cells in puncture of serous ovarian cystomas and cystadenocarcinomas]."
5.	Pancreatectomy 04/01/1998 - "There was also a cystic lesion in the pancreas, and subsequent distal pancreatectomy revealed a cystadenocarcinoma of the pancreas. " 09/01/1991 - "A distal pancreatectomy was performed after a diagnosis of cystadenocarcinoma. " 01/01/1987 - "Total pancreatectomy was performed under the diagnosis of cystadenocarcinoma. " 06/01/1985 - "[An autopsy performed on a pancreatic cystadenocarcinoma patient who received total pancreatectomy ten years ago]." 05/30/1981 - "Total excision of a cystadenocarcinoma in a third case required 90% pancreatectomy with ensuing diabetes. "